The Food and Drug Administration Feb. 5 released an alert notifying patients of a safety concern using diabetes devices such as continuous glucose monitors, insulin pumps and automated insulin dosing systems that rely on a smartphone for delivering alerts. The agency said it received medical device reports in which users reported alerts were not being delivered or heard in situations where the users thought they configured the alerts to be delivered. Some instances may have contributed to serious harm, including severe hypoglycemia, severe hyperglycemia, diabetic ketoacidosis and death.   

The FDA issued recommendations for users and said it is working with diabetes-related medical device manufacturers to ensure that smartphone alert configurations are evaluated prior to use. It is also working with manufacturers to ensure settings for smartphones and mobile medical applications are continuously tested and that updates are communicated quickly and clearly to users.

Related News Articles

Headline
In part two of a recent blog, AHA National Advisor for Cybersecurity and Risk John Riggi and AHA Deputy National Advisor for Cybersecurity and Risk Scott Gee…
AHA Cyber Intel
In part one of this blog, we reviewed the number of cyberattacks the health care field endured this year compared to last; provided an overview of the lessons…
Headline
The Cybersecurity and Infrastructure Security Agency Oct. 15 released an emergency directive advising federal agencies to take stock of their F5 BIG-IP…
Headline
In a video on the AHA’s Care Delivery Transformation Framework, hospital leaders from Rutgers Health/RWJ Barnabas Health and Yale New Haven Health System…
Headline
In part one of a new blog, John Riggi, AHA national advisor for cybersecurity and risk, and Scott Gee, AHA deputy national advisor for cybersecurity and risk,…
Perspective
Public
This week, the FBI issued an urgent warning to all users — including hospitals — of a critical security soft spot within Oracle’s E-Business Suite, stating “…